Lazarov

STATEMENT OF FACTS

In March 2018, Lazarov presented to the hospital for the first time with suicidal thoughts. He was diagnosed with depression and hospitalized for one week. Dr. Shaulov began treating Lazarov in late May 2018 for anxiety and depression.1 Before May, Lazarov had seen another psychiatrist who had prescribed him numerous medications, including Cymbalta, Clonazepam, and Trazodone. Dr. Shaulov opted to continue these medications and added a prescription for Neurontin. Over the course of 10 subsequent visits between June 11 and September 25, 2018, Lazarov reported experiencing persistent and worsening anxiety, feelings of general unwellness, and dread. At each of these visits, Dr. Shaulov adjusted Lazarov’s existing medications, added new medications, or did both. On June 11, 2018, Dr. Shaulov discontinued the Neurontin prescription and added Rexulti. On June 25, he discontinued the Rexulti and increased the Cymbalta dosage. On July 11, he added Effexor and

We have gleaned many of the facts pertinent to Lazarov’s

medical condition and treatment from the declaration submitted to the court by Dr. Shaulov’s psychiatric expert, Stephen M. Stahl, M.D., Ph.D., in…